BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 16954472)

  • 1. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification.
    Asgharzadeh S; Pique-Regi R; Sposto R; Wang H; Yang Y; Shimada H; Matthay K; Buckley J; Ortega A; Seeger RC
    J Natl Cancer Inst; 2006 Sep; 98(17):1193-203. PubMed ID: 16954472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
    Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
    Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of MYCN amplification with MCM7 protein expression in neuroblastomas: a chromogenic in situ hybridization study in paraffin sections.
    Tsai HY; Hsi BL; Hung IJ; Yang CP; Lin JN; Chen JC; Tsai SF; Huang SF
    Hum Pathol; 2004 Nov; 35(11):1397-403. PubMed ID: 15668898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study.
    Moreau LA; McGrady P; London WB; Shimada H; Cohn SL; Maris JM; Diller L; Look AT; George RE
    Clin Cancer Res; 2006 Oct; 12(19):5693-7. PubMed ID: 17020972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYCN gene amplification in patients with neuroblastic tumors.
    Estiar MA; Fazilaty H; Aslanabadi S; Seifi M; Varghaei P; Rezamand A
    Cell Mol Biol (Noisy-le-grand); 2014 Sep; 60(3):23-8. PubMed ID: 25231001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling.
    Schramm A; Schulte JH; Klein-Hitpass L; Havers W; Sieverts H; Berwanger B; Christiansen H; Warnat P; Brors B; Eils J; Eils R; Eggert A
    Oncogene; 2005 Nov; 24(53):7902-12. PubMed ID: 16103881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature.
    Tomioka N; Oba S; Ohira M; Misra A; Fridlyand J; Ishii S; Nakamura Y; Isogai E; Hirata T; Yoshida Y; Todo S; Kaneko Y; Albertson DG; Pinkel D; Feuerstein BG; Nakagawara A
    Oncogene; 2008 Jan; 27(4):441-9. PubMed ID: 17637744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
    Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
    Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of MYCN and ID2 overexpression in neuroblastoma.
    Alaminos M; Gerald WL; Cheung NK
    Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.
    de Souza DR; Sanabani SS; de Souza AC; Filho Odone V; Epelman S; Bendit I
    Pediatr Blood Cancer; 2011 May; 56(5):749-56. PubMed ID: 21154590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients.
    Combaret V; Audoynaud C; Iacono I; Favrot MC; Schell M; Bergeron C; Puisieux A
    Cancer Res; 2002 Jul; 62(13):3646-8. PubMed ID: 12097268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma.
    Alaminos M; Davalos V; Cheung NK; Gerald WL; Esteller M
    J Natl Cancer Inst; 2004 Aug; 96(16):1208-19. PubMed ID: 15316056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
    Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
    Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
    Hu HL; He LJ
    Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma.
    Haber M; Smith J; Bordow SB; Flemming C; Cohn SL; London WB; Marshall GM; Norris MD
    J Clin Oncol; 2006 Apr; 24(10):1546-53. PubMed ID: 16575006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implication of unfavorable histology, MYCN amplification and diploidy for stage I and II neuroblastomas.
    de Buys Roessingh AS; Rougemont AL; Wiesenauer C; Barrette S; Bouron-Dal Soglio D; Lallier M
    Eur J Pediatr Surg; 2008 Dec; 18(6):410-4. PubMed ID: 19012235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
    Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
    Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
    Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
    Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis.
    Shimada H; Stram DO; Chatten J; Joshi VV; Hachitanda Y; Brodeur GM; Lukens JN; Matthay KK; Seeger RC
    J Natl Cancer Inst; 1995 Oct; 87(19):1470-6. PubMed ID: 7674334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of MYCN amplification in patients with stage 4 neuroblastoma who undergo intensive chemotherapy.
    Suita S; Tajiri T; Kaneko M; Hirai M; Mugishima H; Sugimoto T; Tsuchida Y
    J Pediatr Surg; 2007 Mar; 42(3):489-93. PubMed ID: 17336185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.